$35.13
4.33% today
Nasdaq, Feb 28, 04:50 pm CET
ISIN
US52490G1022
Symbol
LEGN
Sector
Industry

Legend Biotech Corp - ADR Stock price

$36.72
+0.08 0.22% 1M
-20.30 35.60% 6M
+4.18 12.85% YTD
-33.27 47.54% 1Y
-2.87 7.25% 3Y
-0.28 0.76% 5Y
-0.28 0.76% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.19 0.52%
ISIN
US52490G1022
Symbol
LEGN
Sector
Industry

Key metrics

Market capitalization $6.74b
Enterprise Value $5.87b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.28
P/S ratio (TTM) P/S ratio 12.95
P/B ratio (TTM) P/B ratio 6.04
Revenue growth (TTM) Revenue growth 122.96%
Revenue (TTM) Revenue $520.18m
EBIT (operating result TTM) EBIT $-351.24m
Free Cash Flow (TTM) Free Cash Flow $-236.25m
Cash position $1.21b
EPS (TTM) EPS $-1.91
P/E forward negative
P/S forward 10.87
EV/Sales forward 9.47
Short interest 13.15%
Show more

Is Legend Biotech Corp - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Legend Biotech Corp - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Legend Biotech Corp - ADR forecast:

25x Buy
93%
2x Hold
7%

Analyst Opinions

27 Analysts have issued a Legend Biotech Corp - ADR forecast:

Buy
93%
Hold
7%

Financial data from Legend Biotech Corp - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
520 520
123% 123%
100%
- Direct Costs 215 215
48% 48%
41%
305 305
210% 210%
59%
- Selling and Administrative Expenses 220 220
22% 22%
42%
- Research and Development Expense 415 415
16% 16%
80%
-329 -329
-
-63%
- Depreciation and Amortization 22 22
-
4%
EBIT (Operating Income) EBIT -351 -351
22% 22%
-68%
Net Profit -348 -348
32% 32%
-67%

In millions USD.

Don't miss a Thing! We will send you all news about Legend Biotech Corp - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Legend Biotech Corp - ADR Stock News

Positive
Seeking Alpha
about 2 months ago
Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. LEGN's flagship product, CARVYKTI, has received multiple regulatory approvals and shows significant sales growth, with potential peak sales of at least $3B. The company has an impressive pipeline (with 11 non-CARVYKTI related programs), high growth rate...
Neutral
GlobeNewsWire
2 months ago
SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT.
Neutral
GlobeNewsWire
3 months ago
SOMERSET, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) provided significantly higher rates of minimal residual disease (MRD)-negativity in patients with relapsed or l...
More Legend Biotech Corp - ADR News

Company Profile

Legend Biotech Corporation develops cell therapy solutions for cancer patients. The company was founded in 2014 and is based in Cayman Islands. The company operates as a subsidiary of Genscript Biotech Corporation.

Head office Cayman Islands
CEO Ying Huang
Employees 1,826
Founded 2014
Website www.legendbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today